GEN Exclusives

More »

GEN News Highlights

More »
Jun 8, 2010

Forest Laboratories Pays TransTech Pharma $50M Up Front in Diabetes Deal

  • Forest Laboratories is paying TransTech Pharma $50 million in a collaboration related to the former’s glucose-lowering agents for the treatment of diabetes. TransTech Pharma could earn a total of $1.105 billion in up-front and milestone fees.

    The license agreement covers the development and commercialization of these small molecule compounds, which are functionally liver-selective glucokinase activators (GKAs). The licensed candidates include lead compound, TTP399, which has completed Phase I studies and other molecules in Phase I and preclinical stages.

    Forest will also pay royalties on worldwide product sales and will be responsible for development and commercialization costs. TransTech Pharma retains rights to the Middle East and North Africa, while Forest receives exclusive rights to the rest of the worldwide market.

    TransTech Pharma’s compounds are covered by composition of matter patents and applications, which currently, in the case of the lead compound TTP399, extend to 2025. The firm has identified a series of liver selective GKA compounds and has advanced three compounds to Phase I trials, including TTP399. The company believes that by activating glucokinase selectively in the liver but not in the pancreas, it may increase glucose utilization and lower blood glucose levels without inducing excessive insulin secretion thus reducing the risk of hypoglycemia.

Readers' Comments

Posted 06/09/2010 by Evelyn Guzman

Forest Laboratories Pays TransTech Pharma $50M Up Front in Diabetes Deal
Wow, imagine paying $50 million for the treatment of diabetes.  And do you know what it is for?  For the blood sugar lowering agents that Trans Tech Pharma is working on, that's what.  Forest Laboratories must have some kind of inside information to fork out that much money.  I can only hope Trans Tech Pharma succeeds not for the sake of Forest Laboratories so they can recoup their substantial investment but for the sake of all the diabetics whose life will become more manageable.   
Evelyn Guzman  (If you want to visit, just click but if it doesn’t work, copy and paste it onto your browser.)

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »